A second of Covid-19 vaccination dose may not be needed for individuals who have successfully recovered from a prior coronavirus infection, suggests a study. The research, involving more than 260 individuals, showed that a single dose of the Pfizer-BioNTech vaccine for individuals who previously had Covid-19, can generate an immunologic response similar to that of individuals receiving the two-dose recommended sequence. The Pfizer and BioNTech vaccine is normally administered in two doses, 21 days apart, to provide nearly full protection against the novel coronavirus, known as SARS-CoV-2. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but it was similar between the two groups after the second dose, the findings, published in the journal Nature Medicine, revealed.
April 03 2021
More than 5,000 cars per day, served by an army of volunteers, has led to more than 85,000 shots.
It s as if the people who built Disneyland reimagined a M A S H unit.
The choreographed craziness of an average day at the mass vaccination site at Portland International Airport is a staggering amalgam of nearly 500 volunteers per day on 22 square acres of the airport s Red Lot, taking in around 5,200 cars filled with people wanting to receive their first or second shot of the anti-coronavirus vaccine. It s 400 orange traffic cones and massive circus tents and the constant roar of incoming aircraft, not that far overhead. It s the military precision of professionals and volunteers many of whom wear goofy hats or wave pompoms and, as of last Friday, the Herculean effort has put more than 85,000 doses of vaccine into the arms of Oregonians anxious for a glimpse of the light at the end of the COVID-19 tunnel.
Shilpa Medicare jumped 5.08% to Rs 350.75 after the company said its board approved sale of its Austrian subsidiary Loba Feinchemie to Austria s ZR Pharma.
The turnover of Loba Feinchemie for the FY 2019-20 was Rs 50.19 crore, representing 5.53% of the consolidated turnover of Shilpa Medicare (Rs 908 crore).
The networth of Loba Feinchemie as on 31 March 2020 was Rs 20.19 crore, which comes to 1.52% of the consolidated networth of Shilpa Medicare (Rs 1321 crore).
The sale agreement was signed on 31 March 2021 and the company expects to complete the sale upon fulfilment of conditions of the share purchase agreement.
The total consideration received from the sale is euro 3.3 million (approximately Rs 28 crore).
Alembic Pharmaceuticals (Alembic) today announced that its joint venture Aleor Dermaceuticals (Aleor) has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram, of Taro Pharmaceuticals U. S.
A. Inc. Nystatin and Triamcinolone Acetonide Cream, USP is indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatinsteroid combination provides greater benefit than the nystatin component alone during the first few days of treatment.
Sun Pharmaceutical Industries announced that DigiHealth Technologies LLP, the wholly owned entity of its Indian wholly owned subsidiary s investee entity i.e.
ABCD Technologies LLP (to be renamed as IndoHealth Services LLP), has agreed to acquire 100% ownership interest in Pharmarack Technologies in tranches.
The upfront acquisition of 91.8% of shareholding in Pharmarack is expected to be completed within a period of 30 (thirty) days by purchase of shares from multiple existing shareholders in various lots.
The remaining 8.2% of the shareholding in Pharmarack is likely to be acquired in multiple tranches over the next 5 (five) years.
Cost of acquisition to DigiHealth Technologies LLP for upfront acquisition of 91.8% is Rs 111 crore.